Clinical trial · Interventional
Resveratrol and Human Hepatocyte Function in Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): No funding
Summary
Brief summary (as posted)
The purpose of this study is to determine if Resveratrol, a nutritional supplement, shows a beneficial effect in the cellular function of normal liver cells and diseased liver cells (cancer cells) in samples of liver tissue taken during elective liver surgery. Outcomes based on 3 measures will test the hypothesis that Resveratrol when used as a nutritional supplement will 1)improve metabolic function in liver cells, 2)reduce cellular growth and proliferation of cancer cells, 3)decrease inflammation in the liver.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo | Drug | — | UNRESOLVED |
| Resveratrol | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- resveratrol
- description
- Resveratrol 1 g daily for 10 days
- interventionNames
- Dietary Supplement: Resveratrol
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Placebo 1 pill daily for 10 days
- interventionNames
- Drug: Placebo
Primary outcomes (1)
- measure
- Improved metabolic profile of liver cells
- timeFrame
- 36 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Undergoing elective liver resection for liver cancer Exclusion Criteria: * Inability to speak or read English * Sclerosing cholangitis, hemochromatosis, hepatic encephalopathy, acute hepatic failure * History of daily alcohol intake * Presence of human immunodeficiency virus * Presence of significant renal dysfunction as defined by baseline serum creatinine \> 2.0 mg/dl or need/impending need for chronic dialysis therapy * Known allergy to the study medication * Pregnancy, lactating women, women contemplating pregnancy during the study period
References
Publications (0)
Data not yet available